Novartis AG NVS
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 97th percentile, 5-year average 18.0x
#2132 of 2972 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 100th percentile, 5-year average 4.8x
#4784 of 5311 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 97th percentile, 5-year average 4.2x
#3971 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 8.16 | – | 4.76 | 100% (pricier than usual) | #4784 of 5311 (1 = cheapest) |
| PE | 30.69 | 19.73 | 17.98 | 97% (pricier than usual) | #2132 of 2972 (1 = cheapest) |
| PS | 5.29 | 5.01 | 4.17 | 97% (pricier than usual) | #3971 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NVS.
Sign in to join the discussion.